Literature DB >> 16383012

Cancer morphology, carcinogenesis and genetic instability: a background.

Leon P Bignold1, B L D Coghlan, H P A Jersmann.   

Abstract

Morphological abnormalities of both the nuclei and the cell bodies of tumour cells were described by Müller in the late 1830s. Abnormalities of mitoses and chromosomes in tumour cells were described in the late 1880s. Von Hansemann, in the 1890s, suggested that tumour cells develop from normal cells because of a tendency to mal-distribution and other changes of chromosomes occurring during mitosis. In the first decades of the 20th century, Mendelian genetics and "gene mapping" of chromosomes were established, and the dominant or recessive bases of the familial predispositions to certain tumour types were recognised. In the same period, the carcinogenic effects of ionising radiations, of certain chemicals and of particular viruses were described. A well-developed "somatic gene-mutational theory" of tumours was postulated by Bauer in 1928. In support of this, in the next three decades, many environmental agents were found to cause mitotic and chromosomal abnormalities in normal cells as well as mutations in germ-line cells of experimental animals. Nevertheless, mitotic, chromosomal, and other mutational theories were not popular explanations of tumour pathogenesis in the first half of the 20th century. Only in the 1960s did somatic mutational mechanisms come to dominate theories of tumour formation, especially as a result of the discoveries of the reactivity of carcinogens with DNA, and that the mutation responsible for xeroderma pigmentosum causes loss of function of a gene involved in the repair of DNA after damage by ultraviolet light (Cleaver in 1968). To explain the complexity of tumourous phenomena, "multi-hit" models gained popularity over "single-hit" models of somatic mutation, and "epigenetic" mechanisms of gene regulation began to be studied in tumour cells. More recently, the documentation of much larger-than-expected numbers of genomic events in tumour cells (by Stoler and co-workers, in 1999) has raised the issue of somatic genetic instability in tumour cells, a field which was pioneered in the 1970s mainly by Loeb. Here these discoveries are traced, beginning with "nuclear instability" though mitotic-and-chromosomal theories, single somatic mutation theories, "multi-hit" somatic theories, "somatic, non-chromosomal, genetic instability" and epigenetic mechanisms in tumour cells as a background to the chapters which follow.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16383012     DOI: 10.1007/3-7643-7378-4_1

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  10 in total

1.  The C/A polymorphism in intron 11 of the XPC gene plays a crucial role in the modulation of an individual's susceptibility to sporadic colorectal cancer.

Authors:  Justyna Gil; Dave Ramsey; Agnieszka Stembalska; Pawel Karpinski; Karolina A Pesz; Izabela Laczmanska; Przemyslaw Leszczynski; Zygmunt Grzebieniak; Maria Malgorzata Sasiadek
Journal:  Mol Biol Rep       Date:  2011-05-11       Impact factor: 2.316

2.  Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.

Authors:  Paul L Crispen; Rosalia Viterbo; Stephen A Boorjian; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

3.  Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.

Authors:  Elaine Soon; Alexi Crosby; Mark Southwood; Peiran Yang; Tamara Tajsic; Mark Toshner; Sarah Appleby; Catherine M Shanahan; Kenneth D Bloch; Joanna Pepke-Zaba; Paul Upton; Nicholas W Morrell
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 30.528

4.  Nuclear morphometry and ploidy of normal and neoplastic haemocytes in mussels.

Authors:  Francesca Carella; Gionata De Vico; Gabriel Landini
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

Review 5.  Microorganisms in the Treatment of Cancer: Advantages and Limitations.

Authors:  Klaudia Łukasiewicz; Marek Fol
Journal:  J Immunol Res       Date:  2018-02-27       Impact factor: 4.818

6.  Nuclear Transport Factor 2 (NTF2) suppresses WM983B metastatic melanoma by modifying cell migration, metastasis, and gene expression.

Authors:  Lidija D Vuković; Pan Chen; Sampada Mishra; Karen H White; Jason P Gigley; Daniel L Levy
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

Review 7.  Mutation or not, what directly establishes a neoplastic state, namely cellular immortality and autonomy, still remains unknown and should be prioritized in our research.

Authors:  Shengming Zhu; Jiangang Wang; Lucas Zellmer; Ningzhi Xu; Mei Liu; Yun Hu; Hong Ma; Fei Deng; Wenxiu Yang; Dezhong Joshua Liao
Journal:  J Cancer       Date:  2022-07-04       Impact factor: 4.478

8.  Use of constitutive and inducible oncogene-containing iPSCs as surrogates for transgenic mice to study breast oncogenesis.

Authors:  Christine Nguyen; Julie P T Nguyen; Arnav P Modi; Ihsaan Ahmad; Sarah C Petrova; Stuart D Ferrell; Sabrina R Wilhelm; Yin Ye; Dorthe Schaue; Sanford H Barsky
Journal:  Stem Cell Res Ther       Date:  2021-05-27       Impact factor: 6.832

9.  Glutathione in cancer cell death.

Authors:  Angel L Ortega; Salvador Mena; Jose M Estrela
Journal:  Cancers (Basel)       Date:  2011-03-11       Impact factor: 6.639

10.  Antiproliferative activity of the isofuranonaphthoquinone isolated from Bulbine frutescens against Jurkat T cells.

Authors:  Penelope Tambama; Berhanu Abegaz; Stanley Mukanganyama
Journal:  Biomed Res Int       Date:  2014-01-16       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.